(Total Views: 248)
Posted On: 02/01/2019 7:49:20 PM
Post# of 154875
Two articles out today.
https://www.proactiveinvestors.com/companies/...13816.html
https://insiderfinancial.com/cytodyn-inc-otcm...-execution
https://www.proactiveinvestors.com/companies/...13816.html
https://insiderfinancial.com/cytodyn-inc-otcm...-execution
Quote:
Bottom line
Currently trading with a market cap of $142 million, CYDY is an exciting story among small caps. We believe that the problems behind CYDY have been related to poor execution by management rather than any issues with the science. We are optimistic that new CMO Richard Pestell can take the company down the field and bring PRO 140 to commercialization. With Dr. Nitya Ray back as Chief Technology Officer, everyone is banking on 2019 being a breakout year for CytoDyn.
Disclosure: We have no position in CYDY and have not been compensated for this article .
(1)
(0)
